Harrow Health, Inc. (HROW) Cash Flow Statement

The gap between net income and operating cash flow is narrow in Q2 2026, but the positive OCF/NI ratio of 0.56 is misleading because it reflects large non-cash add-backs like D&A and SBC, which totaled $9.4M combined. Excluding these, cash generation from core operations is deeply negative, suggesting that reported losses understate the true cash burn. Investors should monitor whether working capital swings, which contributed -$8.7M in Q2, continue to drain liquidity as the company scales its branded sales force.

The FCF trajectory is highly erratic, with a peak of $19.5M in Q1 2025 followed by a collapse to -$55.3M in Q4 2024, driven by a massive working capital outflow of -$35.1M. The most recent quarter shows a modest improvement from Q1 2026's -$9.2M, but the negative FCF margin of -13.5% indicates that revenue growth is not yet translating into sustainable cash generation. This pattern suggests that the company's cash flow is heavily dependent on timing of collections and payables, rather than underlying profitability, warranting close attention to the second-half acceleration narrative.

The working capital line item is the most volatile component of operating cash flow, swinging by over $60M between Q4 2024 and Q1 2025, which suggests significant timing issues in receivables and payables. In Q2 2026, a -$8.7M working capital outflow contributed to the negative operating cash flow, indicating that the company may be extending credit to customers or building inventory ahead of expected sales. This volatility obscures the underlying cash-generating ability of the business and makes quarterly comparisons unreliable, so investors should focus on trailing twelve-month trends rather than single quarters.

Harrow's capital deployment is entirely oriented toward growth through acquisitions, with no shareholder returns in the form of dividends or buybacks over the past ten quarters. The acquisition outflows, while modest in absolute terms, signal a strategy of portfolio expansion that has contributed to the elevated debt-to-equity ratio of 4.84. Given the negative free cash flow in most quarters, the company appears to be funding these acquisitions through debt, which increases financial risk and limits flexibility if revenue growth stalls.

The cumulative divergence between net income and operating cash flow is stark: net losses total -$57.4M, yet operating cash flow is barely positive at $3.2M, indicating that non-cash charges like SBC and D&A are inflating cash flow relative to earnings. This suggests that the company's cash-generating ability is weaker than the income statement implies, as large working capital outflows and heavy reinvestment consume any operational cash. The persistent negative net income, combined with minimal cumulative operating cash flow, raises questions about the sustainability of the business model without continued external financing.